Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma

Table 3 Theraputic effectiveness comparison between camrelizumab plus apatinib and hepatic artery infusion chemotherapy group and camrelizumab plus apatinib and hepatic artery infusion chemotherapy-microwave ablation group

Variables	TRIPLET group (n = 122)	TRIPLET-MWA group (n = 95)	P value	TRIPLET group (n = 82)	TRIPLET-MWA group (n = 82)	P value
Hepatic response
Tumor response to the first TRIPLET			0.062			0.120
Non-OR	90 (73.77)	54 (60.67)		58 (70.73)	45 (57.69)
OR	32 (26.23)	35 (39.33)		24 (29.27)	33 (42.31)
The optimal tumor response			< 0.001			0.007
Non-OR	38 (31.15)	9 (9.47)		21 (25.61)	7 (8.54)
OR	84 (68.85)	86 (90.53)		61 (74.39)	75 (91.46)	0.006
Overall response			0.001
Non-OR	46 (37.70)	15 (15.79)		28 (34.15)	12 (14.63)
OR	76 (62.30)	80 (84.21)		54 (65.85)	70 (85.37)
HAIC sessions1	4 (2, 6)	4 (2, 6)	1.000	4 (2, 6)	4 (2, 6)	1.000
Interval between TRIPLET and MWA, day1		40 (32, 53)			36 (32, 48)

¹The qualitative data using median with interquartile range in two groups were compared by using the χ² test.

Data are number of patients; data in parentheses are percentage unless otherwise indicated and data in bracket was percent of patients. TRIPLET: Camrelizumab plus apatinib and hepatic artery infusion chemotherapy; HCC: Hepatocellular carcinoma; HAIC: Hepatic arterial infusion chemotherapy; MWA: Microwave ablation; PSM: Propensity score match; OR: Objective response.